EP0424021A1 — Antimuscarinic bronchodilators
Assigned to Pfizer Ltd Great Britain · Expires 1991-04-24 · 35y expired
What this patent protects
Compounds having the formula: wherein X is either (a) a phenyl group optionally substituted by 1 or 2 substituents each independently selected from halo, CR₃, C₁-C₄ alkyl, C₁-C₄ alkoxy and hydroxy, or (b) a thienyl group; and Y is an imidazolyl, pyrazolyl, triazolyl or tetr…
USPTO Abstract
Compounds having the formula: wherein X is either (a) a phenyl group optionally substituted by 1 or 2 substituents each independently selected from halo, CR₃, C₁-C₄ alkyl, C₁-C₄ alkoxy and hydroxy, or (b) a thienyl group; and Y is an imidazolyl, pyrazolyl, triazolyl or tetrazolyl group optionally substituted by 1 or 2 substituents each independently selected from halo, CF₃, C₁-C₄ alkoxy, hydroxy and amino; and pharmaceutically acceptable salts thereof, are antimuscarinic bronchodilators useful in the treatment of chronic obstructive airways disease and asthma.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.